Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Alessia Mennitto

6PUBLICATIONS

29CO-AUTHORS

Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targets

Featured researcher

Get your video featured.

Publish with JoVE

Featured researcher

Get your video featured.

Publish with JoVE

Publications (6)

Sort by Publication Date:

|Jan 28, 2026

Long-Term Oncological Outcomes in Metastatic Prostate Cancer Patients Who Are Able to Maintain/Recover Ongoing Anticancer Therapy After SARS-CoV-2 Infection-Results of the MEET-URO 22 Study.

Orazio Caffo, Umberto Basso, Antonello Veccia

|Jan 21, 2023

Pembrolizumab Plus Axitinib for Metastatic Papillary and Chromophobe Renal Cell Carcinoma: NEMESIA (Non Clear MEtaStatic Renal Cell Carcinoma Pembrolizumab Axitinib) Study, a Subgroup Analysis of I-RARE Observational Study (Meet-URO 23a).

Marco Stellato, Sebastiano Buti, Marco Maruzzo

|Apr 12, 2022

Apalutamide, Darolutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC): A Critical Review.

Carlo Cattrini, Orazio Caffo, Ugo De Giorgi

|Nov 05, 2021

Cabozantinib beyond progression improves survival in advanced renal cell carcinoma patients: the CABEYOND study (Meet-URO 21).

Alessia Mennitto, Emma Zattarin, Massimo Di Maio

|Jan 21, 2021

Radical metastasectomy followed by sorafenib versus observation in patients withclear cell renal cell carcinoma: extended follow -up of efficacy results from the randomized phase II RESORT trial.

A Mennitto, E Verzoni, F Cognetti

|Nov 06, 2020

Effects of cabozantinib on bone turnover markers in real-world metastatic renal cell carcinoma.

Raffaele Ratta, Elena Verzoni, Alessia Mennitto

Pageof 1

Frequent Collaborators

3 joint publications

Giuseppe Procopio

2 joint publications

Elena Verzoni

2 joint publications

Ugo De Giorgi

2 joint publications

Franco Morelli

2 joint publications

Francesco Pierantoni

2 joint publications

Melanie Claps

2 joint publications

Valentina Guadalupi

2 joint publications

Orazio Caffo

2 joint publications

Filippo G De Braud

2 joint publications

Sebastiano Buti

Frequent Collaborators

3 joint publications

Giuseppe Procopio

2 joint publications

Elena Verzoni

2 joint publications

Ugo De Giorgi

2 joint publications

Franco Morelli

Top Related Videos

Application of Ha-CoV-2 Pseudovirus for Rapid Quantification of SARS-CoV-2 Variants and Neutralizing Antibodies

Application of Ha-CoV-2 Pseudovirus for Rapid Quantification of SARS-CoV-2 Variants and Neutralizing Antibodies

Published on : Sep 08, 2023

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on : Feb 07, 2021

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on : Mar 06, 2018

See more related videos

Top Related Videos

Application of Ha-CoV-2 Pseudovirus for Rapid Quantification of SARS-CoV-2 Variants and Neutralizing Antibodies

Application of Ha-CoV-2 Pseudovirus for Rapid Quantification of SARS-CoV-2 Variants and Neutralizing Antibodies

Published on : Sep 08, 2023

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on : Feb 07, 2021

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on : Mar 06, 2018

See more related videos